MX2020010199A - Polipeptidos antigenicos del virus sincitial respiratorio. - Google Patents

Polipeptidos antigenicos del virus sincitial respiratorio.

Info

Publication number
MX2020010199A
MX2020010199A MX2020010199A MX2020010199A MX2020010199A MX 2020010199 A MX2020010199 A MX 2020010199A MX 2020010199 A MX2020010199 A MX 2020010199A MX 2020010199 A MX2020010199 A MX 2020010199A MX 2020010199 A MX2020010199 A MX 2020010199A
Authority
MX
Mexico
Prior art keywords
respiratory syncytial
syncytial virus
antigenic
virus polypeptides
polypeptides
Prior art date
Application number
MX2020010199A
Other languages
English (en)
Inventor
Kurt Swanson
Pradeep Dhal
Magnus Besev
Gary J Nabel
Chih- Jen Wei
Ram Dharanipragada
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MX2020010199A publication Critical patent/MX2020010199A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta divulgación versa sobre polipéptidos antigénicos del virus sincitial respiratorio (VSR) para su uso en la obtención de anticuerpos contra el VSR. También se divulgan polipéptidos antigénicos que comprenden un polipéptido del VSR y una proteína ferritina.
MX2020010199A 2018-04-03 2019-04-02 Polipeptidos antigenicos del virus sincitial respiratorio. MX2020010199A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862652199P 2018-04-03 2018-04-03
PCT/US2019/025387 WO2019195291A1 (en) 2018-04-03 2019-04-02 Antigenic respiratory syncytial virus polypeptides

Publications (1)

Publication Number Publication Date
MX2020010199A true MX2020010199A (es) 2021-01-08

Family

ID=66182672

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020010199A MX2020010199A (es) 2018-04-03 2019-04-02 Polipeptidos antigenicos del virus sincitial respiratorio.

Country Status (10)

Country Link
US (1) US12071454B2 (es)
EP (1) EP3773704A1 (es)
JP (1) JP2021519597A (es)
KR (1) KR20210018206A (es)
CN (1) CN112512567A (es)
AU (1) AU2019247034A1 (es)
BR (1) BR112020019938A2 (es)
CA (1) CA3095175A1 (es)
MX (1) MX2020010199A (es)
WO (1) WO2019195291A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112512567A (zh) 2018-04-03 2021-03-16 赛诺菲 抗原性呼吸道合胞病毒多肽
WO2019195314A2 (en) 2018-04-03 2019-10-10 Sanofi Antigenic epstein barr virus polypeptides
EP3773698A1 (en) 2018-04-03 2021-02-17 Sanofi Ferritin proteins
US20230302112A1 (en) 2021-11-05 2023-09-28 Sanofi Respiratory synctial virus rna vaccine
WO2023201222A1 (en) * 2022-04-11 2023-10-19 Vanderbilt University Ferritin nanoparticles and methods of use thereof
WO2024041773A1 (en) * 2022-08-22 2024-02-29 Glaxosmithkline Biologicals Sa Rsv-f proteins
WO2024078597A1 (en) * 2022-10-13 2024-04-18 Rvac Medicines (Us) , Inc. Rsv f protein variants and uses thereof
WO2024094881A1 (en) 2022-11-04 2024-05-10 Sanofi Respiratory syncytial virus rna vaccination
CN117586359A (zh) * 2024-01-19 2024-02-23 北京安百胜生物科技有限公司 一种具有免疫原性的呼吸道合胞病毒（rsv）多肽

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083795B1 (en) 1993-08-06 2006-08-01 Sanofi Pasteur Limited Inactivated respiratory syncytial viral vaccines
US5585250A (en) 1993-08-20 1996-12-17 The United States Of America As Represented By The Department Of Health & Human Services Dampening of an immunodominant epitope of an antigen for use in plant, animal and human compositions and immunotherapies
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
CA2194761C (en) 1994-07-15 2006-12-19 Arthur M. Krieg Immunomodulatory oligonucleotides
JP2001513776A (ja) 1997-02-28 2001-09-04 ユニバーシティ オブ アイオワ リサーチ ファウンデーション ＬＰＳ関連障害の処置における非メチル化ＣｐＧジヌクレオチドを含む核酸の使用
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
WO1998052581A1 (en) 1997-05-20 1998-11-26 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
CA2323929C (en) 1998-04-03 2004-03-09 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
EP1272840A1 (en) 2000-04-03 2003-01-08 The Board Of Trustees Of The Leland Stanford Junior University A method for protein structure alignment
DE60131982T2 (de) 2000-08-18 2008-12-11 Brookhaven Science Associates Llc Veränderte borrelia burgdorferi ospa
CN105566497A (zh) 2002-05-10 2016-05-11 新世纪药品有限公司 融合铁蛋白在疫苗和其他方面的应用
US7774185B2 (en) 2004-09-14 2010-08-10 International Business Machines Corporation Protein structure alignment using cellular automata
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
CN101951950A (zh) 2007-12-21 2011-01-19 葛兰素史密丝克莱恩生物有限公司 疫苗
BRPI0821532A2 (pt) 2007-12-24 2015-06-16 Id Biomedical Corp Quebec Antígenos de rsv recombinantes
US20110117131A1 (en) 2008-04-09 2011-05-19 Ning Huang Production of OspA for Lyme Disease Control
SG172022A1 (en) 2008-12-09 2011-07-28 Novavax Inc Modified rsv f proteins and methods of their use
WO2011008974A2 (en) 2009-07-15 2011-01-20 Novartis Ag Rsv f protein compositions and methods for making same
KR102085465B1 (ko) 2010-05-14 2020-03-05 박스알타 인코퍼레이티드 키메라 ｏｓｐａ 유전자, 단백질 및 이의 사용 방법
WO2012006180A1 (en) 2010-06-29 2012-01-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv immunogens
CA2832106A1 (en) 2011-04-07 2012-10-11 Neotope Biosciences Limited Compositions and methods for treating diseases of protein aggregation involving ic3b deposition
JP5795184B2 (ja) 2011-04-22 2015-10-14 国立大学法人 奈良先端科学技術大学院大学 被検物質の電気化学的検出方法
EP2515112B1 (en) 2011-04-22 2015-08-12 Sysmex Corporation Method for electrochemically detecting analyte
US20140348865A1 (en) 2011-09-12 2014-11-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Ser. Immunogens based on an hiv-1 v1v2 site-of-vulnerability
CN116162175A (zh) * 2011-09-20 2023-05-26 西奈山伊坎医学院 流感病毒疫苗及其应用
CA2849822C (en) 2011-09-23 2021-05-11 Gary J. Nabel, M.D. Novel influenza hemagglutinin protein-based vaccines
WO2014018858A2 (en) 2012-07-26 2014-01-30 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Multimeric fusion protein vaccine and immunotherapeutic
KR20220139415A (ko) * 2013-03-13 2022-10-14 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 선융합(prefusion) RSV F 단백질 및 이의 용도
BR112016007868A2 (pt) 2013-10-11 2017-12-05 Us Health vacinas contra o vírus de epstein-barr
CZ2014320A3 (cs) 2014-05-09 2015-11-18 VÝZKUMNÝ ÚSTAV VETERINÁRNÍHO LÉKAŘSTVÍ, v.v.i. Polyepitopový antigen, vakcinační konstrukt a vakcína pro prevenci lymeské boreliózy
WO2015183969A1 (en) * 2014-05-27 2015-12-03 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Stabilized influenza hemagglutinin stem region trimers and uses thereof
US9703095B2 (en) 2015-01-05 2017-07-11 Edward Pakhchyan Light modulator for MEMS display
WO2016138160A1 (en) * 2015-02-24 2016-09-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
AU2016362597C1 (en) 2015-12-04 2022-05-26 Dana-Farber Cancer Institute, Inc. Vaccination with MICA/B alpha 3 domain for the treatment of cancer
EP3436064A1 (en) * 2016-03-29 2019-02-06 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Substitutions-modified prefusion rsv f proteins and their use
AR108781A1 (es) 2016-06-07 2018-09-26 Deutsches Krebsforsch Aumento de la inmunogenicidad del péptido l2 de virus de papiloma humano (hpv)
BR112018076015A8 (pt) 2016-06-17 2022-06-28 Sanofi Pasteur Formulações imunogênicas compreendendo adjuvantes de polímero do ácido poliacrílico linear ou ramificado .
US10961283B2 (en) 2016-06-27 2021-03-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Self-assembling insect ferritin nanoparticles for display of co-assembled trimeric antigens
CN118085055A (zh) 2017-04-19 2024-05-28 生物医学研究所 作为疫苗及新疟疾疫苗和抗体结合靶标的疟原虫子孢子npdp肽
EP3713601A4 (en) 2017-11-21 2022-03-09 Modernatx, Inc. VACCINES AGAINST EPSTEIN-BARR VIRUS
EP3773698A1 (en) 2018-04-03 2021-02-17 Sanofi Ferritin proteins
CA3095174A1 (en) 2018-04-03 2019-10-10 Sanofi Antigenic ospa polypeptides
WO2019195314A2 (en) 2018-04-03 2019-10-10 Sanofi Antigenic epstein barr virus polypeptides
CN112512567A (zh) 2018-04-03 2021-03-16 赛诺菲 抗原性呼吸道合胞病毒多肽
EP3773703A1 (en) 2018-04-03 2021-02-17 Sanofi Antigenic influenza-ferritin polypeptides

Also Published As

Publication number Publication date
EP3773704A1 (en) 2021-02-17
WO2019195291A1 (en) 2019-10-10
JP2021519597A (ja) 2021-08-12
RU2020135568A (ru) 2022-05-06
KR20210018206A (ko) 2021-02-17
CA3095175A1 (en) 2019-10-10
CN112512567A (zh) 2021-03-16
US20210017237A1 (en) 2021-01-21
AU2019247034A1 (en) 2020-10-22
BR112020019938A2 (pt) 2021-01-26
US12071454B2 (en) 2024-08-27

Similar Documents

Publication Publication Date Title
MX2020010199A (es) Polipeptidos antigenicos del virus sincitial respiratorio.
WO2019195314A3 (en) Antigenic epstein barr virus polypeptides
PH12018501882A1 (en) Binding proteins and methods of use thereof
EP4223784A3 (en) Compositions and methods for modulating t-cell mediated immune response
MY172997A (en) Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
MX2019006349A (es) Proteinas recombinantes rsv f de prefusion nuevas y usos de las mismas.
MX2018015755A (es) Proteinas de hemaglutinina de virus de influenza y usos de las mismas.
EA202190906A1 (ru) Рекомбинантное получение препаратов пептидов коллагена и их применение
WO2018187356A3 (en) Protein antigens and uses thereof
MX2021001129A (es) Metodo de purificacion de antigenos.
WO2018160896A8 (en) Selecting headache patients responsive to antibodies directed against calcitonin gene related peptide
EP3626747A4 (en) NEW RECOMBINANT BIFUNCTIONAL FUSION PROTEIN, PROCESS OF PREPARATION AND USE
MX2020009116A (es) Proteinas triespecificas de union a antigenos.
EP3615060A4 (en) HSV ANTIGENIC PEPTIDES AND HSV PROTEIN VACCINES
WO2013150309A8 (en) Clostridium difficile antigens
EP3851455C0 (en) MONOCLONAL ANTIBODIES SPECIFIC BINDING FOR HUMAN AND MONKEY CD38 ANTIGEN, METHODS FOR ITS PRODUCTION AND USE
WO2015112558A3 (en) Peptides, devices, and methods for the detection of anaplasma antibodies
ZA202101260B (en) Long-acting recombinant glp1-fc-cd47 protein, preparation method and use thereof
IL281203A (en) Pneumococcal fusion protein vaccines
EP4054343C0 (en) EXTENDED WHEY PROTEIN HYDROLYSATE WITH TOLERogenic PEPTIDES
PH12019502449A1 (en) Anti-jagged1 antigen binding proteins
EP3634145A4 (en) POLYPEPTIDE, USE AND PROCESS FOR HYDROLYSIS OF PROTEIN
EP3804748A4 (en) Phosphorylated polypeptide antigen vaccine, preparation method therefor and application thereof
MX2018003445A (es) Expresion de proteinas que contienen fc.
EP3741774A4 (en) N-TERMINAL FUSION PARTNER FOR THE MANUFACTURING OF A RECOMBINANT POLYPEPTID AND PROCESS FOR THE MANUFACTURING OF A RECOMBINANT POLYPEPTID USING THESE